Guest
British Ivermectin Recommendation Development Panel – Response to EMA Statement on Ivermectin for Covid-19 On 22 March, the European Medicines Agency (EMA) issued a statement [0] that, after reviewing the evidence, they recommend against the use of ivermectin for the prevention and treatment of covid-19, outside of ‘well-designed’ clinical trials. The EMA claims evidence from laboratory studies, clinical trials, observational studies, and meta-analysis, but provides no sources, specifics or citations. We fill these omissions below. The British Ivermectin Recommendation Development (BIRD) panel was set up in January 2021 by Dr Tess Lawrie of the Evidence-Based Medicine Consultancy Ltd (E-BMC), an independent medical research company based in Bath, UK. A systematic review and meta-analysis of ivermectin for covid-19 was recently conducted by Dr Lawrie, the director, with a team of expert systematic reviewers. A preliminary report was released in the public domain on 3 Janua
